Profil
Steven N.
Avruch is currently the Director at the Boston Center for the Arts.
Previously, he served as the Chief Counsel, VP & Assistant Secretary at Biogen, Inc. from 2015 to 2017.
He also held the position of Secretary & Chief Legal Officer at AVROBIO, Inc. from 2020 to 2024.
Mr. Avruch completed his undergraduate degree at Dartmouth College and his graduate degree at Boston College Law School.
Postes actifs de Steven Avruch
| Sociétés | Poste | Début |
|---|---|---|
Boston Center for the Arts
Boston Center for the Arts Media ConglomeratesConsumer Services Provides multidisciplinary support and venue services for artists via residencies, exhibitions, performances & engagement program | Directeur/Membre du Conseil | - |
Anciens postes connus de Steven Avruch
| Sociétés | Poste | Fin |
|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Conseiller Juridique Général | 20/06/2024 |
| BIOGEN INC. | Conseiller Juridique Général | 01/12/2017 |
Formation de Steven Avruch
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Dartmouth College
Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boston Center for the Arts
Boston Center for the Arts Media ConglomeratesConsumer Services Provides multidisciplinary support and venue services for artists via residencies, exhibitions, performances & engagement program | Consumer Services |
Boston College Law School
Boston College Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AVROBIO, Inc.
AVROBIO, Inc. BiotechnologyHealth Technology Develops potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases in a single dose | Health Technology |
















